MentionFox
Home › Executive changes › Serina Therapeutics, Inc.
Leadership changes · SEC Form 8-K, Item 5.02

Serina Therapeutics, Inc. executive changes

Every leadership change Serina Therapeutics, Inc. reported to the SEC under Item 5.02: who left, who was appointed, to what role and from when, quoted from each filing.

Filings3
Appointments named1
Latest filing2026-07-23

Serina Therapeutics, Inc. filed 3 current reports with the SEC under Item 5.02, which covers directors and officers leaving or being appointed, the latest on 2026-07-23. Between them they name 1 person. Each change below is quoted from the filing and linked to it.

Every change, newest first

Filed 2026-07-23 · 8-K

Reported

The A&R Employment Agreement also contains confidentiality, non-competition (two years following termination), non-solicitation and no-hire (18 months following termination), and non-disparagement covenants.
Filed 2026-07-22 · 8-K

Reported

On July 22, 2026, Serina Therapeutics, Inc. (the "Company") issued a press release announcing the appointment of Farrell Simon, Pharm.
Filed 2026-04-21 · 8-K

Appointed: Srini Tenjarla, Chief Technology Officer

Chief Technology Officer On April 20, 2026, Serina Therapeutics (AL), Inc. (the " Serina (AL) "), a wholly owned subsidiary of Serina Therapeutics, Inc. (the " Company "), named Srini Tenjarla, Ph.D., its Chief Technology Officer.
Hiring for a seat like this?

Find people with the same kind of experience as the Chief Technology Officer at Serina Therapeutics, Inc., with the record behind each one.

Find candidates like Chief Technology Officer at Serina Therapeutics, Inc.
Selling to Serina Therapeutics, Inc.?

New leaders review vendors and budgets in their first months. Get an alert the next time Serina Therapeutics, Inc. is in the news or changes leadership.

Get an alert when Serina Therapeutics, Inc. changes leadership

Tools for this story

Each opens in a new tab, filled in for Serina Therapeutics, Inc.. With no account yet, you sign up free and land on the result.

Where this comes from

A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.

Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.

Cite this page

Permanent URL: https://mentionfox.com/executive-changes/serina-therapeutics
Last updated 2026-09-27
Primary record: SEC filing 1 · SEC filing 2 · SEC filing 3
Serina Therapeutics, Inc. (SER) executive changes: 3 leadership filings. MentionFox, 2026-09-27. https://mentionfox.com/executive-changes/serina-therapeutics